Aeglea BioTherapeutics Announces Leadership Change

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts.

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry

Aileron Therapeutics Announces Pricing of Initial Public Offering

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency

Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts

Coherus Biosciences receives complete response letter from FDA for its biologics license application for CHS-1701 (pegfilgrastim biosimilar candidate)

Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species

Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis

Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee

Coherus Biosciences prevails in ‘135 IPR decision

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation to advance protein homeostasis medicines to benefit patients.

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel for Cancer Treatment

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

Aeglea Biotherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting

Aeglea Biotherapeutics to Present Topline Data from Phase 1 Trial of AEB1102

FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer

Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint

Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease

FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson’s research

Protagonist Therapeutics Presents Data on Oral Peptide

Coherus prices public offering of common stock